Payment overview · 2025
General Payments
$27,733.60
69 reported records · 14 companies
Healthcare provider profile · identity verified
Markus Ploesser, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · CHULA VISTA, CA · NPI 1669662755
Verified facts
What the public records show
CMS Open Payments records show Markus Ploesser, MD received $27,733.60 in general payments during 2025 across 69 reported records.
Alkermes, Inc. accounted for 54.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Lybalvi, Uzedy.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Lybalvi by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIVITROL as an associated drug or biological on 9533 records involving 5661 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vivitrol by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UZEDY as an associated drug or biological on 46702 records involving 13355 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Uzedy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $15,071.99 | 54.4% | 28 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $11,124.47 | 40.1% | 12 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$348.91 | 1.3% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $214.03 | 0.8% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $203.46 | 0.7% | 5 | 2025 |
| Avanos Medical | Unresolved — no canonical attribution shown | $163.09 | 0.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $161.98 | 0.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $146.57 | 0.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $94.42 | 0.3% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $84.79 | 0.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $50.41 | 0.2% | 2 | 2025 |
| SPR Therapeutics, Inc | Unresolved — no canonical attribution shown | $24.11 | 0.1% | 1 | 2025 |
| Neuronetics, Inc. | Unresolved — no canonical attribution shown | $23.20 | 0.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.17 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,920.00 | 6 |
| Consulting Fee | $7,460.00 | 2 |
| Food and Beverage | $2,758.95 | 57 |
| Travel and Lodging | $1,594.65 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $14,951.56 | 27 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $11,124.47 | 12 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $355.42 | 12 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $214.03 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $203.46 | 5 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $175.00 | 1 | 2025 |
Source payment records
|
|||||
| COOLIEF COOLED RADIOFREQUENCY Normalized: coolief cooled radiofrequency |
Device | Avanos Medical | $163.09 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $161.98 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $146.57 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA INITIO Normalized: aristada initio |
Drug | Alkermes, Inc. | $120.43 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $94.42 | 4 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $93.53 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $84.79 | 3 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $64.22 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $50.41 | 2 | 2025 |
Source payment records
|
|||||
| SPRINT PNS System Normalized: sprint pns system |
Device | SPR Therapeutics, Inc | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| NEUROSTAR TMS THERAPY SYSTEM Normalized: neurostar tms therapy system |
Device | Neuronetics, Inc. | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| ACCURIAN Normalized: accurian |
Device | Medtronic, Inc. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 50 | exact normalized | Medicare Part D |
| UZEDY uzedy |
2025 | Uzedy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | VIVITROL open payments reported associated product |
CMS Open Payments — General Payments 9533 supporting records · 5661 recipient NPIs · example record 1222428584 |
Vivitrol · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | UZEDY open payments reported associated product |
CMS Open Payments — General Payments 46702 supporting records · 13355 recipient NPIs · example record 1247244226 |
Uzedy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Bupropion Xl | Bupropion Hcl | 70 | 12 |
| Buspirone Hcl | Buspirone Hcl | 56 | 14 |
| Olanzapine | Olanzapine | 55 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 51 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 50 | 13 |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Metformin Hcl | Metformin Hcl | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Uzedy | Risperidone | 16 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Vivitrol | Naltrexone Microspheres | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $27,733.60 · 69 records | Alkermes, Inc. | ACCURIAN, ARISTADA, ARISTADA INITIO, CAPLYTA, COBENFY, COOLIEF COOLED RADIOFREQUENCY, ETERNA, FANAPT, General - Pain Management, INCEPTIV, INGREZZA, INTELLIS ADAPTIVESTIM, LYBALVI, NEUROSTAR TMS THERAPY SYSTEM, REXULTI, SPRINT PNS System, SYNCHROMEDII, UZEDY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Lybalvi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Alkermes, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error